Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.

Creak A, Hall E, Horwich A, Eeles R, Khoo V, Huddart R, Parker C, Griffin C, Bidmead M, Warrington J, Dearnaley D.

Br J Cancer. 2013 Aug 6;109(3):651-7. doi: 10.1038/bjc.2013.394. Epub 2013 Jul 23.

2.

DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.

Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C.

Cancer Immunol Immunother. 2012 Nov;61(11):2161-70. doi: 10.1007/s00262-012-1270-0. Epub 2012 May 22.

3.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.

4.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators.

Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.

5.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

6.

Radiotherapy planning in high-grade gliomas: a survey of current UK practice.

Creak AL, Tree A, Saran F.

Clin Oncol (R Coll Radiol). 2011 Apr;23(3):189-98. doi: 10.1016/j.clon.2010.11.003. Epub 2011 Feb 1.

PMID:
21288703
7.

Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.

Saran F, Baumert BG, Creak AL, Warrington AP, Ashley S, Traish D, Brada M.

Pediatr Blood Cancer. 2008 Mar;50(3):554-60.

PMID:
17941071
8.

Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy?

Creak AL, Harrington K, Nutting C.

Clin Oncol (R Coll Radiol). 2005 May;17(3):138-47. Review.

PMID:
15900996

Supplemental Content

Loading ...
Support Center